



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/626,477	07/23/2003		Martin Keller	564462008100	3798
45975	7590	03/13/2006		EXAMINER	
DIVERSA			LU, FRANK WEI MIN		
12531 HIGF SUITE 100	12531 HIGH BLUFF DRIVE SUITE 100				PAPER NUMBER
SAN DIEGO	O, CA 9	2130-2040	1634		
				DATE MAILED: 03/13/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

-	Application No.	Applicant(s)
	10/626,477	KELLER, MARTIN
Office Action Summary	Examiner	Art Unit
	Frank W. Lu	1634
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		•
Responsive to communication(s) filed on This action is FINAL. 2b)⊠ This Since this application is in condition for allower closed in accordance with the practice under E	action is non-final.	
Disposition of Claims		
4)	vn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine 11).	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	акенк Аррикаціон (ЕТО-192)

Application/Control Number: 10/626,477

Art Unit: 1634

DETAILED ACTION

Page 2

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-36, drawn to a method for isolating and maintaining a cell from a mixed population of uncultivated cells, classified in class 435, subclass 7.1.

II. Claims 37 and 38, drawn to a method for identifying a polynucleotide encoding an activity of interest, classified in class 435, subclass 6.

2. The inventions are distinct, each from the other because of the following reasons:

Groups I and II are distinct and independent inventions in that they are directed to methods which have different purposes. As a result, different and distinct searches will have to be performed. For example, the search required for Group I such as isolating and maintaining a cell from a mixed population of uncultivated cells of claim 1 is not required for Group II while the search required for Group II such as identifying a polynucleotide encoding an activity of interest of claim 37 is not required for Group I.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

- 3. Group I contains claims directed to the following patentably distinct species:
- (1) the porous gel microdroplet (GMD) comprises a hydrogel matrix (claim 13)
- (2) the porous gel microdroplet (GMD) comprises a selectively permeable membrane (claim

13)

(3) the porous gel microdroplet (GMD) comprises a CELMIXTM emulsion matrix (claim 14)

(4) the porous gel microdroplet (GMD) comprises a CELGELTM encapsulation matrix (claim

14)

The species are independent or distinct because these species are directed to different porous gel microdroplets.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, generic claims are claims 1-12 and 15-36.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 4. Group I further contains claims directed to the following patentably distinct species:
- (5) the growth column comprises a capillary (claim 17)
- (6) the growth column comprises a chromatography column (claim 18)

The species are independent or distinct because these species are directed to different growth columns.

Application/Control Number: 10/626,477

Page 4

Art Unit: 1634

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, generic claims are claims 1-16 and 19-36.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 5. Group I further contains claims directed to the following patentably distinct species:
- (7) conditions allowing the encapsulated cell to survive and be maintained comprise providing nutrients at in situ concentrations (claim 21)
- (8) conditions allowing the encapsulated cell to survive and be maintained comprise flowing an aqueous nutrient mixture through the growth column (claim 22)

The species are independent or distinct because these species are directed to different conditions allowing the encapsulated cell to survive and be maintained.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, generic claims are claims 1-20 and 23-36.

Application/Control Number: 10/626,477 Page 5

Art Unit: 1634

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

6. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571)273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571)272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Frank Lu Primary Examiner March 7, 2006

> FRANK LU PRIMARY EXAMINER

Muleur